CAS 1072833-77-2
:Ixazomib
- MLN 2238
- B-[(1R)-1-[[2-[(2,5-Dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid
- Ninlaro
- Boronic acid, B-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-
- Ixazomib
[(1R)-1-{2-[(2,5-dichlorophenyl)formamido]acetamido}-3-methylbutyl]boronic acid
CAS:Fórmula:C14H19BCl2N2O4Pureza:98%Cor e Forma:SolidPeso molecular:361.0287Ref: IN-DA0037YJ
1gA consultar2gA consultar5gA consultar5mg66,00€10mg100,00€25mg169,00€50mg168,00€100mg205,00€250mg602,00€Ixazomib
CAS:Ixazomib (MLN2238) is a boron-based peptide proteasome inhibitor targeting β5 site (IC50: 3.4 nM), also affecting β1 and β2 sites.Fórmula:C14H19BCl2N2O4Pureza:98% - 99.77%Cor e Forma:SolidPeso molecular:361.03Ixazomib
CAS:Produto ControladoApplications Ixazomib is a proteasome inhibitor that acts by preventing cell growth in solid tumours. It is an anticancer agent that is used to treat patients with multiple myeloma and is potentially neurotoxic.
References Anderson, K.: J. Nat. Comp. Canc. Net., 12, 808 (2014); Chattopadhyay, N., et al.: Mol. Cancer Ther., 12, B156 (2013); Vallet, S. & Podar, K.: Exp. Opin. Biol. Ther., 13, S35 (2013)Fórmula:C14H19BCl2N2O4Cor e Forma:NeatPeso molecular:361.03Ixazomib-13C2,15N
CAS:Produto ControladoApplications Ixazomib-13C2,15N is derived from (αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetic Acid Salt (P458505), which is a Bortezomib (B675700) intermediate. A boronic acid dipeptide derivative as proteasome inhibitors.
References Kisselev, A., et al.: Chem. Biol., 8, 739 (2001), Kisselev, A., et al.: J. Biol. Chem., 278, 35869 (2003), Verdoes, M., et al.: Chem. Biol., 13, 1217 (2006)Fórmula:C1213C2H19BCl2N15NO4Cor e Forma:White To Off-WhitePeso molecular:364.01Ixazomib
CAS:Proteosome inhibitor; antineoplastic
Fórmula:C14H19BCl2N2O4Pureza:Min. 95%Cor e Forma:PowderPeso molecular:361.03 g/mol






